Is Teva (NYSE:TEVA) genuinely concerned about Biogen's  (NASDAQ:BIIB) BG-12's safety, or is it more concerned about the oral MS drug's impact to its own Copaxone sales? Motley Fool health-care analyst David Williamson dives into the surprise plea to the FDA and what it means for investors.